INmune Bio (NASDAQ:INMB) Given New $30.00 Price Target at Maxim Group

INmune Bio (NASDAQ:INMB) had its target price upped by Maxim Group from $22.00 to $30.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also recently issued reports on the stock. Alliance Global Partners began coverage on shares of INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 price objective for the company. Rodman & Renshaw began coverage on INmune Bio in a report on Tuesday, January 28th. They set a “buy” rating and a $23.00 target price on the stock. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Scotiabank lifted their price objective on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $22.80.

INmune Bio Stock Up 1.9 %

Shares of INMB opened at $9.30 on Thursday. INmune Bio has a 52-week low of $4.32 and a 52-week high of $14.74. The stock has a market cap of $206.18 million, a PE ratio of -4.27 and a beta of 1.87. The firm’s fifty day moving average is $6.44 and its two-hundred day moving average is $6.11.

Institutional Trading of INmune Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Praetorian PR LLC lifted its holdings in INmune Bio by 61.0% in the third quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after acquiring an additional 295,800 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of INmune Bio in the 4th quarter valued at $2,221,000. Geode Capital Management LLC grew its holdings in shares of INmune Bio by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 363,602 shares of the company’s stock worth $1,698,000 after purchasing an additional 19,136 shares during the period. State Street Corp grew its holdings in shares of INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after purchasing an additional 58,838 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of INmune Bio by 73.3% during the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company’s stock worth $868,000 after purchasing an additional 78,600 shares during the last quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.